[Form 4] Inhibikase Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing overview: On 06/30/2025, Inhibikase Therapeutics, Inc. (IKT) granted Director Arvind Kush a stock option for 108,176 shares of common stock at an exercise price of $1.95 per share. The option is classified as a derivative security and is held directly by the reporting person.

Vesting & expiration: The option vests on the earlier of (i) June 30, 2026 or (ii) the day before the company’s next annual shareholder meeting, provided the director remains in service through that date. It expires on 06/30/2032.

Post-grant ownership: Following the transaction, Kush beneficially owns 108,176 derivative securities (options) with no change in non-derivative share holdings disclosed. No shares were sold or disposed of in this filing.

Key takeaway: The filing reflects routine director compensation, increasing insider exposure to future share-price appreciation without immediate cash outflow.

Positive

• Director received 108,176 stock options, increasing long-term equity exposure and aligning board incentives with shareholder interests.
• No shares were sold or disposed of, indicating commitment rather than profit-taking.

Negative

• None.

Insights

Financial Analyst

TL;DR Routine option grant; aligns director incentives, no immediate share sale, neutral near-term market impact.

The grant of 108,176 options at $1.95 is standard board compensation and does not involve cash transactions or stock disposals. The one-year vesting schedule ensures continued board engagement. Because no open-market buying or selling occurred, the filing is largely informational with minimal trading signal. The size of the grant is modest for a micro-cap biotech and does not materially change insider ownership percentages disclosed elsewhere. Overall, the filing is neutral for valuation but slightly positive for governance alignment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kush Arvind

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.95	06/30/2025		A		108,176		(1)	06/30/2032	Common Stock	108,176	$0	108,176	D

Explanation of Responses:

1. The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ David McIntyre, attorney-in-fact	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 for IKT report on 06/30/2025?

Director Arvind Kush received an option to purchase 108,176 shares at $1.95.

When do the newly granted IKT options vest?

They vest on the earlier of June 30, 2026 or the day before the next annual shareholder meeting.

Did the insider sell any Inhibikase shares?

No. The Form 4 shows only an option grant; there were no disposals.

What is the expiration date of the IKT options granted to Arvind Kush?

The options expire on June 30, 2032.

How many derivative securities does Arvind Kush own after the transaction?

He beneficially owns 108,176 derivative securities (stock options).